Literature DB >> 9855642

Agonist action of adenosine triphosphates at the human P2Y1 receptor.

R K Palmer1, J L Boyer, J B Schachter, R A Nicholas, T K Harden.   

Abstract

The agonist selectivity for adenosine di- and triphosphates was determined for the human P2Y1 receptor stably expressed in human 1321N1 astrocytoma cells and was studied under conditions in which nucleotide metabolism was both minimized and assessed. Cells were grown at low density on glass coverslips, encased in a flow-through chamber, and continuously superfused with medium, and Ca2+ responses to nucleotides were quantified. Superfusion with high performance liquid chromatographically purified ADP, ATP, 2-methylthio-ADP, and 2-methylthio-ATP resulted in rapid Ca2+ responses, with EC50 values of 10 +/- 5, 304 +/- 51, 2 +/- 1, and 116 +/- 50 nM, respectively. Similar peak responses were observed with maximal concentrations of these four agonists and with the hydrolysis-resistant adenine nucleoside triphosphate adenosine-5'-O-(3-thiotriphosphate). No conversion of [3H]ATP to [3H]ADP occurred under these conditions. Similar full agonist activities of ATP, 2-methylthio-ATP, and ADP were observed in human embryonic kidney 293 cells, which natively express the P2Y1 receptor. In contrast to these results, Leon et al. [FEBS Lett 403:26-30 (1997)] and Hechler et al. [Mol Pharmacol 53:727-733 (1998)] recently reported that, whereas ADP and 2-methylthio-ADP were agonists, ATP and 2-methylthio-ATP were weak antagonists in studies of the human P2Y1 receptor expressed in human Jurkat cells. To assess whether differences in the degree of receptor reserve might explain this discrepancy of results, P2Y1 receptor-expressing 1321N1 cells were incubated for 24 hr with adenosine-5'-O-(2-thiodiphosphate), with the goal of down-regulating the level of functional receptors. Pretreatment with adenosine-5'-O-(2-thiodiphosphate) resulted in a 10-fold rightward shift in the concentration-effect curve for ADP; in contrast, the agonist activity of ATP was completely abolished. Taken together, our results indicate that adenosine di- and triphosphates are agonists at the human P2Y1 receptor. However, the intrinsic efficacy of ATP is less than that of ADP, and the capacity of ATP to activate second messenger responses through this receptor apparently depends on the degree of P2Y1 receptor reserve.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855642

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  51 in total

1.  P2Y(1) purinoceptor-mediated Ca(2+) signaling and Ca(2+) wave propagation in dorsal spinal cord astrocytes.

Authors:  S R Fam; C J Gallagher; M W Salter
Journal:  J Neurosci       Date:  2000-04-15       Impact factor: 6.167

2.  Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.

Authors:  Gary L Waldo; James Corbitt; José L Boyer; Gnana Ravi; Hak Sung Kim; Xiao-Duo Ji; James Lacy; Kenneth A Jacobson; T Kendall Harden
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

Review 3.  Molecular recognition at purine and pyrimidine nucleotide (P2) receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi; Michihiro Ohno; Bhalchandra V Joshi; Pedro Besada; Bin Xu; Susanna Tchilibon
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

Review 4.  Signalling and pharmacological properties of the P2Y receptor.

Authors:  T K Harden; J I Sesma; I P Fricks; E R Lazarowski
Journal:  Acta Physiol (Oxf)       Date:  2010-03-24       Impact factor: 6.311

5.  [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors.

Authors:  Dayle Houston; Michihiro Ohno; Robert A Nicholas; Kenneth A Jacobson; T Kendall Harden
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

6.  Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta.

Authors:  Pieter-Jan D F Guns; András Korda; Herta M Crauwels; Tim Van Assche; Bernard Robaye; Jean-Marie Boeynaems; Hidde Bult
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 7.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

8.  The synthesis and initial characterization of an immobilized purinergic receptor (P2Y1) liquid chromatography stationary phase for online screening.

Authors:  Ruin Moaddel; Enrica Calleri; Gabriella Massolini; Chester R Frazier; Irving W Wainer
Journal:  Anal Biochem       Date:  2007-02-22       Impact factor: 3.365

9.  Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Mol Pharmacol       Date:  2017-09-01       Impact factor: 4.436

10.  Clathrin adaptor AP2 regulates thrombin receptor constitutive internalization and endothelial cell resensitization.

Authors:  May M Paing; Christopher A Johnston; David P Siderovski; Joann Trejo
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.